Targeting Novel but Less Common Driver Mutations and Chromosomal Translocations in Advanced Non-Small Cell Lung Cancer.

about

Frequency of actionable alterations in epidermal growth factor receptor wild type non-small cell lung cancer: experience of the Wide Catchment Area of Romagna (AVR)

P2860

Q58804420-F112DDF5-8145-4E44-A892-0A6D12B3DDAA

P2860

Targeting Novel but Less Common Driver Mutations and Chromosomal Translocations in Advanced Non-Small Cell Lung Cancer.

Item

http://www.wikidata.org/entity/Q42369856

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Targeting Novel but Less Commo ...... ed Non-Small Cell Lung Cancer.

@en

Targeting Novel but Less Commo ...... ed Non-Small Cell Lung Cancer.

@nl

type

Item

label

Targeting Novel but Less Commo ...... ed Non-Small Cell Lung Cancer.

@en

Targeting Novel but Less Commo ...... ed Non-Small Cell Lung Cancer.

@nl

prefLabel

Targeting Novel but Less Commo ...... ed Non-Small Cell Lung Cancer.

@en

Targeting Novel but Less Commo ...... ed Non-Small Cell Lung Cancer.

@nl

P1476

Targeting Novel but Less Commo ...... ed Non-Small Cell Lung Cancer.

@en

P2093

Alia Daoud

http://www.w3.org/2001/XMLSchema#string

Quincy S Chu

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer genome landscapes

The discoidin domain receptor tyrosine kinases are activated by collagen

The PI3K pathway as drug target in human cancer

Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.

Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.

ROS1 rearrangements define a unique molecular class of lung cancers.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.

P304

222

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FONC.2017.00222

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29034207

http://www.w3.org/2001/XMLSchema#string

P932

5626928

http://www.w3.org/2001/XMLSchema#string

Targeting Novel but Less Common Driver Mutations and Chromosomal Translocations in Advanced Non-Small Cell Lung Cancer.

about

P2860

P2860

Targeting Novel but Less Common Driver Mutations and Chromosomal Translocations in Advanced Non-Small Cell Lung Cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932